Coagadex Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Coagadex market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period was driven by factors such as increased awareness of rare bleeding disorders, a rise in the number of hemophilia A patients, higher global healthcare spending, an increase in clinical trials, and growth in the number of healthcare professionals.

In the forecast period, growth is expected to be fueled by greater awareness of rare bleeding disorders, increased investments in research and development, rising healthcare expenditures, a growing number of clinical trials, and expanding healthcare insurance coverage models. Key trends anticipated for this period include technological advancements, the adoption of gene therapies, personalized medicine, integrated healthcare solutions, and the incorporation of digital health tools.

The growing prevalence of rare bleeding disorders is expected to drive the expansion of the coagadex market in the coming years. Rare bleeding disorders are a group of uncommon conditions that hinder the blood's ability to clot, leading to excessive bleeding or difficulty stopping bleeding after injury. The rise in these disorders can be attributed to factors such as improved diagnosis, greater awareness, better healthcare access, and genetic influences. Coagadex is used to treat rare bleeding disorders such as hereditary Factor X deficiency by replacing the missing clotting factor, helping to effectively manage bleeding episodes. For example, in November 2023, the National Library of Medicine reported that as of July 18, 2022, 10,276 individuals with hemophilia were enrolled across 87 treatment centers in 40 countries. Of these, nearly half (49%, or 5,084 patients) had severe hemophilia; 99% were male, 85% had hemophilia A, and 67% were from low- to middle-income countries. Therefore, the rising prevalence of rare bleeding disorders is fueling the growth of the coagadex market.

The development of innovative treatments for Factor X deficiency and the expansion of the market are key trends driving the growth of the coagadex market. Factor X deficiency medications are designed to replace or activate factor X, a critical clotting factor, to prevent or control bleeding in individuals with this rare genetic disorder. For example, in May 2024, Bio Products Laboratory (BPL), a UK-based pharmaceutical company, received orphan drug marketing authorization for Coagadex in Mexico. Coagadex is the first and only treatment specifically designed for hereditary Factor X deficiency, a rare condition that impairs blood clotting due to insufficient factor X in the bloodstream, leading to severe, life-threatening bleeding episodes. The approval of Coagadex in Mexico is particularly important due to the limited epidemiological data on ultra-rare bleeding disorders and the lack of awareness among healthcare professionals about the condition.

In September 2022, the Permira Funds, a UK-based private equity firm, in partnership with the Marcucci family, completed their investment in Kedrion Biopharma and Bio Products Laboratory (BPL), marking a significant merger in the biopharmaceutical sector. This partnership combines two leading companies specializing in developing therapeutic products derived from human blood plasma, creating a global leader in the market for rare disease treatments. Kedrion Biopharma is a US-based company that produces blood and plasma-derived products, while Bio Products Laboratory (BPL) is a UK-based manufacturer of Coagadex.

The key company operating in the coagadex market is Bio Products Laboratory Limited.

North America was the largest region in the coagadex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in coagadex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the coagadex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Coagadex is a medication used to treat hemophilia B, a rare bleeding disorder. Its active ingredient, recombinant coagulation factor IX, is a clotting factor that helps manage bleeding. Individuals with hemophilia B lack or have insufficient levels of factor IX, which is essential for blood clotting. Coagadex works by replacing this missing factor, thereby preventing and managing bleeding episodes. It is administered through intravenous (IV) injection.

The primary indications for coagadex include hereditary factor X deficiency and other coagulation disorders. Hereditary factor X deficiency is a rare genetic condition caused by a lack of sufficient or functional factor X, a key protein involved in blood clotting. Coagadex is distributed through channels such as direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies. It is commonly used in hospitals, clinics, homecare settings, and ambulatory surgical centers.

The coagadex market research report is one of a series of new reports that provides coagadex market statistics, including coagadex industry global market size, regional shares, competitors with a coagadex market share, detailed coagadex market segments, market trends and opportunities, and any further data you may need to thrive in the coagadex industry. This coagadex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The coagadex market consists of sales of factor IX concentrates, factor VIII concentrates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.